97 related articles for article (PubMed ID: 30304341)
1. Treatment of Severe Hailey-Hailey Disease With Apremilast.
Kieffer J; Le Duff F; Montaudié H; Chiaverini C; Lacour JP; Passeron T
JAMA Dermatol; 2018 Dec; 154(12):1453-1456. PubMed ID: 30304341
[TBL] [Abstract][Full Text] [Related]
2. Patients' perspective, quality of life and treatment goals in Hailey-Hailey disease: Lessons learned from the German National Registry.
Rogner D; Heimerl L; Heyer S; Biedermann T; Sattler E; Zink A
J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):419-429. PubMed ID: 37863661
[TBL] [Abstract][Full Text] [Related]
3. Hailey-Hailey disease: the clinical features, response to treatment and prognosis.
Burge SM
Br J Dermatol; 1992 Mar; 126(3):275-82. PubMed ID: 1554604
[TBL] [Abstract][Full Text] [Related]
4. Ineffectiveness of apremilast in moderate-to-severe pemphigus: A case series of three patients.
Zhang Q; Yu L; Wan L; Chen L; Chen J
Australas J Dermatol; 2024 May; ():. PubMed ID: 38783774
[No Abstract] [Full Text] [Related]
5. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Pavel A; Yao C; Kimmel G; Nia J; Hashim P; Vekaria AS; Taliercio M; Singer G; Karalekas R; Baum D; Mansouri Y; Lebwohl MG; Guttman-Yassky E
Arch Dermatol Res; 2019 Jan; 311(1):29-36. PubMed ID: 30417279
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review.
Sondag M; Verhoeven F; Guillot X; Prati C; Wendling D
Clin Rheumatol; 2019 Feb; 38(2):591-596. PubMed ID: 30328022
[TBL] [Abstract][Full Text] [Related]
7. Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
Vossen ARJV; van der Zee HH; Davelaar N; Mus AMC; van Doorn MBA; Prens EP
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):761-765. PubMed ID: 30451329
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.
Li H; Zuo J; Tang W
Front Pharmacol; 2018; 9():1048. PubMed ID: 30386231
[TBL] [Abstract][Full Text] [Related]
9. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
Knuckles MLF; Levi E; Soung J
J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
[No Abstract] [Full Text] [Related]
10. Successful treatment of refractory Hailey-Hailey disease with apremilast.
Di Altobrando A; Sacchelli L; Patrizi A; Bardazzi F
Clin Exp Dermatol; 2020 Jul; 45(5):604-605. PubMed ID: 31930532
[No Abstract] [Full Text] [Related]
11. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis vulgaris associated with systemic lupus erythematosus successfully treated with apremilast.
Ichiyama S; Hoashi T; Kanda N; Hashimoto H; Matsushita M; Nozawa K; Ueno T; Saeki H
J Dermatol; 2019 Jun; 46(6):e219-e221. PubMed ID: 30536461
[No Abstract] [Full Text] [Related]
13. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
14. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
[TBL] [Abstract][Full Text] [Related]
15. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
Sacchelli L; Patrizi A; Ferrara F; Bardazzi F
Dermatol Ther; 2018 Nov; 31(6):e12719. PubMed ID: 30358044
[No Abstract] [Full Text] [Related]
16. Systemic therapies of pityriasis rubra pilaris: a systematic review.
Kromer C; Sabat R; Celis D; Mössner R
J Dtsch Dermatol Ges; 2019 Mar; 17(3):243-259. PubMed ID: 30520557
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with successful switching between biologic therapies for the treatment of psoriasis in daily dermatological real-life practice: The Resoswitch study.
Dabouz F; Khemis A; Barbe C; Lahfa M; Maccari F; Chaby G; Beneton N; Boye T; Esteve E; Mahé E; Begon E; Pauwels C; Bernard P; Taieb C; Reguiai Z;
Dermatol Ther; 2019 Mar; 32(2):e12789. PubMed ID: 30488520
[No Abstract] [Full Text] [Related]
18. YouTube videos on oral systemic therapies for psoriasis: a cross-sectional analysis.
Reynolds KA; Pithadia DJ; Lee EB; Wu JJ
J Dermatolog Treat; 2019 Sep; 30(6):549. PubMed ID: 30457412
[No Abstract] [Full Text] [Related]
19. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535.
Ellis AG; Flohr C; Drucker AM
Br J Dermatol; 2019 Feb; 180(2):282-288. PubMed ID: 30347448
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
